



Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization

Albert Henry, María Gordillo-Marañón, Chris Finan, F Schmidt, João Pedro Ferreira, Ravi Karra, Johan Sundström, Lars Lind, Johan Ärnlöv, Faiez Zannad, et al.

► To cite this version:

Albert Henry, María Gordillo-Marañón, Chris Finan, F Schmidt, João Pedro Ferreira, et al.. Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. Circulation, 2022, 10.1161/CIRCULATIONAHA.121.056663 . hal-03613727

HAL Id: hal-03613727

<https://hal.univ-lorraine.fr/hal-03613727>

Submitted on 18 Mar 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization

Running title: *Lumbers et al.; Proteogenomic Target Identification for HF*

Albert Henry, MD, MSc^{1,2,3}; María Gordillo-Marañón, MSc^{1,2}; Chris Finan, PhD^{1,2,4}; Amand F Schmidt, MSc, PhD^{1,2,4}; João Pedro Ferreira, MD, PhD^{5,6}; Ravi Karra, MD, MHS^{7,8}; Johan Sundström, MD, PhD^{9,10}; Lars Lind, MD, PhD⁹; Johan Ärnlöv, MD, PhD^{11,12}; Faiez Zannad, MD, PhD⁶; Anders Mälarstig, MSc, PhD^{13,14*}; Aroon D. Hingorani, MBBS, PhD, FRCP^{1,2*};

R. Thomas Lumbers, MB BChir, PhD^{2,3,15*}; HERMES and SCALLOP Consortia

¹Institute of Cardiovascular Science, University College London, London, UK; ²British Heart Foundation Research Accelerator, University College London, London, UK; ³Institute of Health Informatics, University College London, London, UK; ⁴Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Heidelberglaan, Utrecht, the Netherlands; ⁵Unic@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; ⁶Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France; ⁷Division of Cardiology, Department of Medicine, Duke University Medical Center; Durham; ⁸Department of Pathology, Duke University Medical Center; Durham, NC; ⁹Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ¹⁰The George Institute for Global Health, University of New South Wales, Sydney, Australia; ¹¹School of Health and Social Studies, Dalarna University, Falun, Sweden; ¹²Division of Family Medicine and Primary Care, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, Sweden;



¹³Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Sweden;

¹⁴Emerging Science & Innovation, Pfizer Worldwide Research, Development and Medical,
Cambridge, MA; ¹⁵Health Data Research UK London, University College London, London,

UK

*These authors contributed equally

Address for Correspondence:

R. Thomas Lumbers, MB BChir, PhD
UCL Institute of Health Informatics
222 Euston Road
London NW1 2DA
Email: t.lumbers@ucl.ac.uk

**This article is published in its accepted form, it has not been copyedited and has not appeared in an issue of the journal. Preparation for inclusion in an issue of Circulation involves copyediting, typesetting, proofreading, and author review, which may lead to differences between this accepted version of the manuscript and the final, published version.



Circulation

Abstract

Background: Heart failure (HF) is a highly prevalent disorder for which disease mechanisms are incompletely understood. The discovery of disease-associated proteins with causal genetic evidence provides an opportunity to identify new therapeutic targets.

Methods: We investigated the observational and causal associations of 90 cardiovascular proteins, which were measured using affinity-based proteomic assays. First, we estimated the associations of 90 cardiovascular proteins with incident heart failure by means of a fixed-effect meta-analysis of four population-based studies, comprising a total of 3,019 participants with 732 HF events. The causal effects of HF-associated proteins were then investigated by Mendelian randomization (MR), using *cis*-protein quantitative loci genetic instruments identified from genome-wide association studies (GWAS) in over 30,000 individuals. To improve the precision of causal estimates, we implemented an MR model that accounted for linkage disequilibrium between instruments and tested the robustness of causal estimates through a multiverse sensitivity analysis that included up to 120 combinations of instrument selection parameters and MR models per protein. The druggability of candidate proteins was surveyed, and mechanism of action and potential on-target side effects were explored with cross-trait MR analysis.

Results: 44/90 proteins were positively associated with risk of incident HF ($P < 6.0 \times 10^{-4}$). Among these, eight proteins had evidence of a causal association with HF that was robust to multiverse sensitivity analysis: higher CSF-1 (macrophage colony-stimulating factor 1), Gal-3 (galectin-3) and KIM-1 (kidney injury molecule 1) were positively associated with risk of HF, whereas higher ADM (adrenomedullin), CHI3L1 (chitinase-3-like protein 1), CTSL1 (cathepsin L1), FGF-23 (fibroblast growth factor 23) and MMP-12 (Matrix metalloproteinase-12) were protective. Therapeutics targeting ADM and Gal-3 are currently under evaluation in clinical trials, and all the remaining proteins were considered druggable, except KIM-1.

Conclusions: We identified 44 circulating proteins that were associated with incident HF, of which eight showed evidence of a causal relationship and seven were druggable, including adrenomedullin which represents a particularly promising drug target. Our approach demonstrates a tractable roadmap for the triangulation of population genomic and proteomic data for the prioritization of therapeutic targets for complex human diseases.

Keywords: Humans, Genome-Wide Association Study, Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase 12, Adrenomedullin, Chitinase-3-Like Protein 1, Fibroblast Growth Factor-23, Galectin 3

Non-standard Abbreviations and Acronyms

AF	Atrial fibrillation
BMI	Body mass index
CAD	Coronary artery disease
<i>cis</i> -MR	Mendelian randomization using <i>cis</i> -acting protein quantitative trait loci instruments
DBP	Diastolic blood pressure
eGFR	Estimated glomerular filtration rate
GWAS	Genome-wide association study
HF	Heart failure
IQR	Inter-quartile range
IVW	Mendelian randomization with inverse-variance weighted estimator
LD	Linkage disequilibrium
MAF	Minor allele frequency
MR	Mendelian randomization
MR-Egger	Mendelian randomization with Egger regression estimator
NPX	Normalized protein expression
Olink CVD-1	Olink® Cardiovascular I circulating protein biomarker panel
PEA	Proximity extension assay
pQTL	Protein quantitative trait loci
RR	Risk ratio
SBP	Systolic blood pressure
SD	Standard deviation
SNP	Single-nucleotide polymorphism
T2D	Type 2 diabetes



Cohort and Consortium Acronyms

Health ABC	Health Aging and Body Composition
HERMES	HEart failuRe Molecular Epidemiology for therapeutic targetS consortium
HOMAGE	Heart OMics in AGEing
PIVUS	Prospective Investigation of the Vasculature in Uppsala Seniors
PREDICTOR	<i>Valutazione della PREvalenza di DISfunzione Cardiaca asinTomatica e di scompenso cardiaco</i>
PROSPER	Prospective Study of Pravastatin in the Elderly at Risk
SCALLOP	Systematic and Combined AnaLysis of Olink Proteins consortium
ULSAM	Uppsala Longitudinal Study of Adult Men

Clinical Perspective

What is new?

- Among 90 proteins investigated for their association with heart failure onset, 44 were observationally associated and eight were causally associated, two of which are the target of drugs in early clinical trials for heart failure.
- Targeting adrenomedullin (ADM) was estimated to protect against new onset HF consistent with the agonist effect of ADM drug antibodies which are under evaluation in clinical trials.

What are the clinical implications?

- Findings provide confirmatory evidence for the development and evaluation of therapeutics targeting galectin-3 and ADM, which are currently being pursued in clinical trials for heart failure.
- Integrating population-scale genomic and proteomic data through triangulation of observational and Mendelian randomization analyses facilitates prioritization of drug targets and provides insights into molecular mechanisms of a complex clinical syndrome.

Introduction

Heart failure (HF) is a clinical syndrome arising from disease processes that either injure or overload the heart muscle leading to inadequate function at normal filling pressures¹. Despite primary prevention through treatment of known antecedent risk factors, prevalence is rising and the burden of associated morbidity and mortality remains high². The challenge of recapitulating a complex age-associated disease entity such as heart failure in model systems is reflected in a history of late-stage failures of new therapeutics in clinical trials^{3–5}. More robust approaches to drug target identification and validation for heart failure are therefore required⁵.

Proteins are frequently the principal regulators of molecular pathways and the target of the vast majority of drugs⁶. The circulating proteome comprises proteins derived from almost all cells and tissues, which are either actively or passively secreted into the circulation or released during cell damage or turnover⁷. Studies of the human circulating proteome measured using affinity or aptamer-based multiplexed assays, have identified a large number of circulating proteins associated with heart failure onset, progression, and recovery^{8–10}. However, the causal relevance of associations from these non-randomized, observational studies (referred as observational associations in the present manuscript) remains largely undetermined; they may arise due to confounding factors, reverse causation, or inclusion of undetected or asymptomatic prevalent cases at time of protein measurement.

Mendelian randomization (MR) can be used to estimate the causal effect of protein levels on disease outcomes¹¹, on condition that three core assumptions are met: that genetic instrumental variables are associated with the exposure (relevance assumption); that they are not associated with confounding factors (independence assumption); and they affect the outcome only through their effects on the exposure of interest (exclusion restriction assumption)^{12,13}. In addition to the biological relevance of proteins, the use of genetic variants

associated with protein level (protein quantitative trait loci or pQTL) as instrumental variables in MR has desirable properties in relation to these assumptions¹⁴ (Figure 1, Supplemental Table 1). pQTL variants are frequently derived from genome-wide association studies (GWAS) using population-based genetic and circulating protein level data^{15,16}, fulfilling the relevance assumption by definition. The selection of genetic instruments mapping to the vicinity of the transcriptional gene unit (*cis*- acting variants), as opposed to those located more remotely (*trans*- acting variants) limits the scope for violating the exclusion restriction assumption, as pQTL variant effects on the outcome are likely mediated through expressions of the protein under consideration (no horizontal pleiotropy)¹⁷. Finally, based on the central dogma of molecular biology, it is implausible that *cis* variant instruments for protein exposures are conditional on the disease outcome and therefore, it is reasonable to assume that protein traits are upstream of the disease outcome in any causal model.

Throughout the manuscript, we refer to this technique as *cis* Mendelian randomization (*cis*-MR), which has been demonstrated to be able to predict efficacy of known drug targets for coronary heart disease¹⁴.

Here, we report an integrated observational and *cis*-MR analyses of circulating protein levels for therapeutic target identification and prioritization in HF, focusing on up to 90 cardiovascular-disease-related circulating proteins measured with Olink CVD-1 multiplexed affinity-based proximity extension assay¹⁸ (Figure 1). We perform meta-analysis of observational associations between circulating protein levels with incident HF^{8,9} estimated from four independent samples. We estimate the causality of these associations with *cis*-MR analysis, by leveraging summary-level data from large genome-wide association studies (GWAS) of circulating levels of proteins under study¹⁵ and HF risk¹⁹. We identify a number of likely causal proteins, report the anticipated effects on HF-related traits estimated through

cross-trait *cis*-MR analysis, and characterize the druggability properties of these proteins as potential therapeutic targets for heart failure.

Methods

Data and Code Availability

For purposes of reproducing the results or replicating the procedure, the data and analysis code used in the main analysis have been made available to other researchers on the following online link: <https://github.com/alhenry/cvd1-hf>. Other supporting data are available within the article, supplemental files, and referenced public datasets.

Circulating Protein Level Measurement

Circulating protein levels were assessed using Olink Proseek Multiplex proximity extension assay (PEA)^{7,18} technology and were quantified in a NPX (normalized protein expression) unit, where 1 unit difference represents a doubling of protein concentration.²⁰ The present study focused on cardiovascular-disease related proteins available on the Olink CVD-1 panel, for which both observational associations with HF and genetic association estimates for *cis*-MR analysis were uniquely available at the time of the study. Observational association estimates with incident HF were available for 90 proteins reported in Ferreira et al. 2019⁹ and Stenemo et al. 2018⁸, of which 88 had autosome-wide genetic association results reported in Folkersen *et al.* (2020)¹⁵. In the observational studies, protein measures were taken at baseline. A detailed description of the methods used for protein quantification and the proteins measured by each of the included studies is provided in Supplemental Note, Supplemental Table 2, and [Figure 1](#).

Study Population for Observational Analysis

We meta-analyzed observational association estimates between circulating protein level and incident HF from four independent samples reported in Ferreira et al. 2019⁹ and Stenemo et

al. 2018⁸: HOMAGE (*Heart OMics in AGEing*)²¹ discovery, HOMAGE validation, PIVUS (*Prospective Investigation of the Vasculature in Uppsala Seniors*)²², and ULSAM (*Uppsala Longitudinal Study of Adult Men*)²³. The HOMAGE discovery and validation samples were derived from two population cohorts and one clinical trial population: Health ABC (Health Aging and Body Composition)²⁴, PREDICTOR (*Valutazione della PREvalenza di Disfunzione Cardiaca asintomatica e di scompenso cardiaco*)^{25,26}, and PROSPER (*Prospective Study of Pravastatin in the Elderly at Risk*)^{27–29}. Individuals with prevalent HF at enrolment were excluded from the analysis. Incident HF was defined as the first diagnosis of HF, ascertained on the basis of hospital record review by trained physicians. The combined sample comprised 3,019 individuals (median age ranged from 70 to 78 years) among whom 732 incident HF events were observed during follow-up (median follow-up time ranged from 1.8 to 10 years). The studies were not able to differentiate between HF with reduced and preserved ejection fraction due to a lack of data on left ventricular ejection fraction. Characteristics of included studies are provided in Table 1 and Supplemental Note and in previous reports^{8,9}.

Statistical Analysis

Meta-analysis of Observational Associations

We performed a fixed-effect meta-analysis using effect estimates from 1) HOMAGE discovery, 2) HOMAGE replication, 3) PIVUS, and 4) ULSAM. Effect estimates for HOMAGE discovery and HOMAGE replication were extracted from odds ratios calculated using multivariable logistic regression adjusting for age, sex, cohort, and follow-up time – which were used as matching variables in a matched, nested case-control design⁹. For PIVUS and ULSAM, effect estimates were taken from hazard ratios calculated using Cox proportional hazard regression adjusting for age and sex⁸. Hazard ratios and odds ratios were assumed to approximate to an equivalent risk ratio (RR), given that the outcome is rare³⁰. To

make results comparable across studies and proteins, study-level circulating protein measures in the NPX unit are standardized by setting the mean to zero and standard deviation (SD) to 1 prior to running regression models, with an assumption that the SDs of circulating protein levels are similar across studies. To account for multiple testing, we implemented a Bonferroni-corrected allowable type-I error rate (α / α) of 0.05 / 90 (number of proteins under study).

Mendelian Randomization Analysis

We assessed the causality of associations for proteins which survived multiple testing correction in the observational analysis by performing two-sample cis-MR using estimates of genetic association with circulating protein levels under study and with heart failure. Genetic associations with circulating protein levels were extracted from a GWAS meta-analysis of 14 cohorts comprising 30,931 subjects of European ancestry included in the SCALLOP (Systematic and Combined AnaLysis of Olink Proteins) consortium¹⁵. Genetic associations with heart failure were extracted from a GWAS meta-analysis of 47,309 all-cause HF cases from 26 studies of European ancestries included in the HERMES (Heart failuRe Molecular Epidemiology for therapeutic targetS) consortium¹⁹. Details of participating studies in each GWAS meta-analysis are provided in Supplemental Table 3 and Supplemental Table 4. Genetic instruments for proteins were selected from all biallelic single-nucleotide polymorphism (SNP)s available in both protein and outcome GWAS summary statistics with MAF >0.01 and located within 200 kbp upstream or downstream of the cognate protein-encoding transcription start and stop sites. Given that a gene *cis*- region constitutes only a small proportion of the genome, we relaxed the conventional genome-wide significance *P* value threshold for instrument selection to $P < 1 \times 10^{-4}$. To allow for an increased statistical power to detect an association, we implemented a relaxed LD r^2 threshold 0.4 and used MR models accounting for residual correlation³¹. This threshold was based on a simulation study

which found that unstable estimates due to multicollinearity started to occur at a threshold correlation of around $r^2 = 0.36$ ³². Using these thresholds, we performed variant clumping implemented in PLINK 1.9³³ to select *cis*- genetic instruments for each protein, with an LD model derived from individual-level HRC-imputed³⁴ genotype data of a random 10,000 UK Biobank³⁵ European participants.

MR estimates were calculated using the Wald ratio estimator for proteins with a single instrument selected, or the inverse-variance weighted (IVW) estimator for proteins with two or more instruments. The Wald ratio estimates are calculated as the regression coefficient for genetic association with the outcome divided by the regression coefficient for genetic association with circulating protein levels. The IVW estimates are calculated as the average of instrument ratio coefficients weighted by the inverse-variance. Both estimates from observational association and MR analyses approximate a risk ratio of HF per 1 SD increase in NPX unit (equivalent to per SD per doubling circulating protein concentration).

Multiverse Sensitivity Analysis for Mendelian Randomization

To test the robustness of estimates from the primary MR analysis, proteins with MR estimates surviving multiple testing correction (P value < 0.05 / numbers of observationally associated proteins with at least 1 instrument) were taken forward to undergo an in-depth, multiverse sensitivity analysis³⁶ in which the stability of the effect estimates was evaluated under a wide combinations of instrument selection parameters and MR models. Thresholds for instrument selection (P value and r^2) and alternative MR models were prioritized over other possible parameters, such as LD reference population and genomic distance, since these parameters were observed to have the greatest influence on estimate stability in a previous systematic evaluation of methods for drug target Mendelian randomization¹⁴. For each MR model, we computed causal estimates for all possible combinations of five LD r^2 thresholds (0.05, 0.1, 0.2, 0.4, and 0.6) and six P -value thresholds (5×10^{-8} , 1×10^{-5} , 1×10^{-4} , 1×10^{-3} , 1

$\times 10^{-2}$, and 1 / no threshold). These combinations included the parameters used in the primary MR analysis above and stringent parameters commonly used in conventional MR analysis of complex trait exposures³⁷. For proteins with a single *cis* instrument, the Wald ratio was the only model that could be tested; where two or more instruments were available, estimates were calculated with: the IVW estimator and MR models using principal components³² with 90% variance and 99% variance explained; and where there were three or more instruments we additionally calculated estimates using MR-Egger¹² ([Supplemental Figure 1](#)). MR with principal components is an alternative model to account for correlation between instruments³², and MR-Egger provides estimates accounting for residual horizontal pleiotropy¹². To reduce spurious associations that may arise due to excess multicollinearity or bias towards the null due to weak instruments in two-sample MR¹⁴, outlier point estimates with value outside 1.5 times the interquartile range (IQR) above the upper quartile and below the lower quartile were removed. An association was declared as robust if all point estimates from the multiverse sensitivity analysis were directionally concordant with estimates from the primary MR analysis, including those based on strict instrument selection parameters and a standard IVW model.

The IVW and MR-Egger estimates were calculated using the *MendelianRandomization* package in R³⁸, with a fixed-effect model for 3 or fewer genetic instruments, or a multiplicative random-effects model otherwise. To minimize erroneously low *P* value due to multicollinearity issue, correlation between instruments was accounted for by incorporating the instrument pairwise LD correlation matrix in the IVW and MR-Egger models^{14,31}. The MR method with principal components was implemented using sample codes from the original publication.³² Genomic coordinates for all relevant analyses were based on Ensembl *GRCh37* reference³⁹.

Cross-trait Mendelian Randomization Analysis

To investigate the potential mechanisms through which candidate target proteins may influence HF risk, we performed an exploratory cross-trait MR to estimate the causal association of genetically-predicted circulating protein levels with common risk factors and comorbidities of HF: coronary artery disease (CAD), atrial fibrillation (AF), estimated glomerular filtration rate (eGFR), systolic blood pressure (SBP), diastolic blood pressure (DBP), type 2 diabetes (T2D), and body mass index (BMI). MR analysis was performed with the primary instrument selection strategy and MR model described above using publicly available GWAS statistics for the relevant traits (Supplemental Table 5)^{40–45}. To allow comparison across protein-trait pairs, effect estimates were converted to Z scores, calculated as log odd ratios divided by their standard errors. The protein-trait MR association was considered potentially causal if the *P* value from the MR analysis was less than a conservative Bonferroni adjusted threshold of 0.05 divided by the number of protein-trait pairs.

Evaluation of Druggability and Clinical Development Activity

We extracted the druggability profile of candidate target proteins from an updated list of druggable genes⁶. To evaluate clinical development activity of candidate drugs targeting the candidate proteins, we queried ChEMBL⁴⁶ (release 27) database to get information on drug molecule types, approved indications, and target outcomes in clinical trials. We complemented this query by performing a manual search through ClinicalTrials.gov website for each candidate target.

Ethical Statement

All included studies were ethically approved by local institutional review boards and all participants provided written informed consent. The analysis was conducted in accordance with guidelines for study procedures provided by the UCL Research Ethics Committee.

Results

Meta-Analysis of Observational Studies Reveals 44 Circulating Proteins Associated with Incident Heart Failure

Through a meta-analysis of observational associations from 4 independent samples, comprising up to 732 incident HF events in 3,019 subjects, we found 44 out of the 90 proteins were associated with incident HF after multiple testing adjustment at $P < 6.0 \times 10^{-4}$ ($\alpha = 0.05/90$ proteins), including 22 associations that were not reported in the individual participating studies^{8,9}. Increasing circulating levels of all the 44 observationally associated proteins showed a risk-increasing effect on incident HF, with a median RR of 1.33 (IQR = 1.26 to 1.46). The largest effect sizes were observed in BNP (RR = 1.92; 95% confidence interval [CI] = 1.70 to 2.18) and NT-proBNP (RR = 1.85; 95% CI = 1.63 to 2.10), two biomarkers which have been routinely used in clinic to diagnose HF. We found no evidence of heterogeneity of the effect estimates after adjustment for multiple testing ($P_{\text{HET}} < 0.05/44$). Full study-level and meta-analysis estimates are provided in Supplemental Table 6.

Causal Effect Estimation with *cis*- Mendelian Randomization

Of the 90 proteins under study, *cis* region genetic association summary statistics were available for 83 proteins encoded by autosomal genes (Supplemental Table 2). *Cis* region sizes varied according to gene length from 401 to 705 kilobase pairs and contained a mean of 1181 variants (standard deviation / SD = 498). Using the primary instrument selection parameter with LD r^2 threshold of 0.4 and P value threshold of 10^{-4} , we identified 75 proteins with 1 to 125 (median = 23) *cis*- genetic instrument, including 40 out of the 44 observationally associated proteins. For comparison, conventional instrument selection parameters (LD $r^2 < 0.05$, $P < 5 \times 10^{-8}$) identified 70 proteins with 1 to 28 (median = 5) *cis*-genetic instruments. Instrument-specific estimates are provided in the accompanying data and code (<https://github.com/alhenry/cvd1-hf/tree/main/resources>).

The primary MR analysis suggested causal relationships for 17 out of the 40 (43%) observationally associated proteins ($P < 0.05/40$). The direction of effects for 16/17 proteins were consistent with those calculated using conventional MR parameters; however, only CHI3L1 survived the multiple testing correction (Figure 2). We also investigated the remaining 35 proteins that did not have an observational association with HF and with at least one *cis*-genetic instrument. Of these, we found additional 9 proteins (26%) with evidence suggestive of a causal association with HF in MR ($P < 0.05 / 35$). Full MR results are provided in Supplemental Table 7.

Multiverse Sensitivity Analysis Demonstrates Robust Causal Estimates for Eight HF-Associated Proteins

Noting that MR estimates are highly sensitive to choice of parameters for instrument and model selection^{17,47}, we tested the stability of the association estimates for each of the 17 HF-associated proteins for which the primary MR analysis suggested underlying causal effects, using a multiverse sensitivity analysis. We tested up to 120 combinations of commonly used parameters for instrument selection and MR models per protein, focusing on parameters which explain the largest variability in MR estimates based on prior simulation and empirical studies^{14,32}, resulting in a total of 1850 individual effect estimates (Supplemental Data 3). We evaluated the distribution of the point estimates generated and compared these with the primary *cis*-MR analysis estimates and with estimates from conventional instrument selection parameters (Figure 2b, Supplemental Table 8). For all 17 proteins under analysis, estimates from the primary *cis*-MR analysis were directionally concordant with median values of the multiverse analysis point estimate distributions and showed overlapping 95% confidence intervals with estimates from *cis*-MR using conventional strict instrument selection parameters.

Further, we identified robust evidence of a causal association with HF as indicated by sign concordance of all MR point estimates from the multiverse sensitivity analysis for eight proteins: ADM (adrenomedullin), CHI3L1 (chitinase-3-like protein 1), CSF-1 (macrophage colony-stimulating factor 1), CTSL1 (cathepsin L1), FGF-23 (fibroblast growth factor 23), Gal-3 (galectin-3), MMP-12 (Matrix metalloproteinase-12), and KIM-1 (kidney injury molecule 1). Increasing circulating levels of all eight proteins were positively associated with risk of incident heart failure in the observational analysis. In the MR analysis, however, only three proteins (CSF-1, Gal-3, and KIM-1) showed positive associations with risk of HF, whereas the remaining five (ADM, CHI3L1, CTSL1, FGF-23, and MMP-12) showed negative associations, suggesting causal protective effects ([Figure 3](#)).

Cross-Trait Mendelian Randomization Analysis for Candidate Therapeutic Targets for Heart Failure



We took forward the eight proteins robustly associated with HF and explored their causal effects on seven HF related traits (CAD, AF, eGFR, SBP, DBP, T2D, and BMI), using the primary *cis*-MR analysis method ([Figure 3](#)). Of the eight candidate proteins, one (ADM) was not associated with any trait other than HF, whereas the remaining seven were associated with at least one other trait after multiple testing correction ($P < 0.05 / 8 \text{ proteins} / 7 \text{ traits excluding HF}$). Consistent with evidence from overexpression perturbation studies in animal models, Gal-3⁴⁸ and CSF-1⁴⁹ were positively associated with BMI, a biomarker of adiposity and a known risk factor for HF⁵⁰. CHI3L1 and CTSL1 were protective for CAD, consistent with reports of cardioprotective effects in animal models of cardiac ischemia^{51,52}. A higher circulating CSF-1 level was associated with an increased risk of CAD⁵³, whereas MMP-12 showed a protective effect, consistent with previous reports¹⁶. A higher level of FGF-23 was associated with a lower estimated glomerular filtration rate (eGFR), consistent with findings

from pre-clinical models where FGF-23 deficiency was associated with worsening renal failure and cardiac hypertrophy⁵⁴.

Appraisal of Druggability and Existing Approved or Clinical-Phase Drug Candidates for Candidate Protein Targets

To evaluate the druggability and drug development activities of candidate targets, we searched through a list of druggable genes⁶, the ChEMBL (release 27) drug discovery database, and a clinical trial registry (<https://clinicaltrials.gov>, accessed on 1 December 2020). We grouped candidate targets into three categories corresponding to the highest status in the drug development pipeline: *approved* (targeted by drugs already approved for one or more conditions), *in development* (currently being investigated in clinical trials), and *druggable* (listed as druggable targets) (Table 2). A candidate drug targeting adrenomedullin, adrecizumab (a humanized, monoclonal, non-neutralizing antibody against the N-terminus of ADM⁵⁵) is entering phase II trials for septic shock (ClinicalTrials.gov identifier: NCT03085758), cardiogenic shock (NCT03989531) and acute heart failure (NCT04252937). A modified citrus pectin (MCP) Gal-3 inhibitor has been evaluated for effects markers of collagen metabolism in patients with hypertension in a proof-of-concept clinical trial for cardiac fibrosis⁵⁶. CSF-1 and MMP-12 inhibitors are currently being evaluated in clinical trials for non-HF conditions. Burosumab, a monoclonal antibody FGF-23 inhibitor, has already been approved for treating X-linked hypophosphatemia and hypophosphatemic rickets. Although we found no ongoing trials specific for CHI3L1 or CTSL1, inhibition of CTSL1 is proposed as potential treatment for SARS-CoV-2 infection and several approved agents show inhibitory activity against CTSL1⁵⁷. With the exception of KIM-1, all seven other proteins are predicted to be secreted in at least one tissue according to the Human Protein Atlas database⁵⁸. KIM-1 is also not currently listed as a potential drug target according to the druggable gene list, ChEMBL release 27, and ClinicalTrials.gov databases.

Discussion

Principal Findings

We investigated 90 circulating proteins for their association with incident heart failure in a population of 3,019 individuals with 732 events. 44 proteins had positive associations with risk of incident heart failure, 22 of which were not reported in the participating studies. These included associations with incident HF reported elsewhere such as Gal-3, HGF and Resistin^{59–61}, proteins such as CXCL16 with reported associations with prognosis in HF⁶², and with cardiac fibrosis on cardiac magnetic resonance imaging in HF including MMP3⁶³. Among the novel associations to highlight, CTSL1, is a potent endoprotease linked to the development of dilated cardiomyopathy and heart failure in mice models^{64,65}. We used *cis*-MR to estimate whether the observational protein-HF associations reflected an underlying causal relationship. Of the 40 proteins for which *cis* genetic instruments were available, 17 showed evidence suggestive of causal effects of which eight were robust to multiverse sensitivity analysis. Among these eight HF-associated proteins, three were positively associated with risk of HF (CSF-1, Gal-3, and KIM-1) and five were negatively associated, consistent with causally protective effects (ADM, CHI3L1, CTSL1, FGF-23, and MMP-12). Seven are known or predicted to be druggable by conventional therapeutic modalities, and therapeutic agents targeting two of the identified proteins are currently under evaluation in phase II clinical trials: Adrecizumab, an ADM agonist, for acute HF and cardiogenic shock⁵⁵, and modified citrus pectin, a Gal-3 antagonist, for cardiac fibrosis⁵⁶. We note that CTSL1 inhibition has been proposed as a potential treatment for COVID-19⁶⁶; our results signal HF as a potential safety liability of this therapeutic approach. Our findings provide evidence supporting the therapeutic hypotheses underpinning two drug development programs for HF and more broadly highlight the emerging opportunities to explore human causal biology of complex disease using population-scale genomic and proteomic data.

Concordance of Observational and Causal Associations for Identified Proteins

One of the key strengths of study is the triangulation of evidence between observational and MR analyses for a consistently measured set of cardiovascular proteins. For all the protein-HF associations that were identified in our meta-analysis, there was a positive association, i.e. a higher protein concentration was associated with an increased risk of incident HF. This is consistent with previously reported biomarker association studies with incident HF, for example, a study of incident HF in the Framingham population identified 18 associated circulating biomarkers of which 17 were positive associations⁶⁷. When we estimated the causal association of the observationally associated HF proteins; however, we found that the observational and causal association estimates were frequently discordant with opposing direction of effects. For example, five proteins with an estimated causally protective effect were found to have a positive association with incident HF, including MMP-12 and ADM. In the case of MMP-12, our findings are consistent with prior reports on the associations between MMP-12 and CAD^{68,16}. These discordant findings may be explained by subclinical or pre-disease leading to higher levels of these proteins that precedes the clinical diagnosis of HF, potentially as an adaptive feedback response to mitigate the disease process. The median baseline age in the included studies ranged from 70-78 years and it is likely that subclinical alterations in cardiac structure and function occurred before incident HF, which was defined as the first HF hospitalization. Concordant observational and causal associations (CSF-1, Gal-3, KIM-1) may be explained either by upstream processes driving risk or by reverse causation where a positive feedback loop exists between the HF and expression of the protein. For several proteins, including established clinical biomarkers NT-pro-BNP and ST2, we found positive observational associations but were unable to detect causal effects by MR analysis. In these the observational associations may be interpreted as non-causal, arising

from reverse causation. We cannot, however, exclude a type 2 error due to imprecision of the MR estimates.

Comparison with Other Studies

To our knowledge, our study represents the first large-scale analysis of incident HF that combines observational associations of circulating proteins with a systematic appraisal of causal effects using MR. Our results were consistent with previously reported findings from MR studies of NT-pro-BNP and GDF-15, which did not report evidence of a strong causal relationship between these proteins and risk of HF^{69,70}. Our approach of triangulating evidence from observational association and MR represents a pragmatic approach to screen and prioritize targets for therapeutic development, according to the relative strength of evidence from analysis of the data available⁷¹. In our study, we used a method for *cis*-MR that incorporates the LD correlation structure within the causal model and provides estimates with higher precision³¹. We combined this primary approach with a new technique to evaluate the robustness of the identified protein-HF associations that involved systematically testing multiple combinations of model parameter selection in a multiverse sensitivity analysis, enabling us to deprioritize proteins with unstable estimates. Using this framework, we found evidence supporting a causal relationship for eight of the 40 HF-associated proteins tested; compared with a single association for CHI3L1 that was identified using conventional approaches. For example, the estimates for CTSL1 and FGF-23 generated with this approach more clearly suggest a causal effect compared with those based on more stringent instrument selection ([Figure 2b](#), Supplemental Table 7).

Implications for Therapeutics Targeting Heart Failure

All eight proteins with estimated causal effects, except ADM, were associated with HF-related traits in an exploratory *cis*-MR cross-trait analysis, including upstream HF risk factors. Distinct pathobiological pathways and proteomic signatures are described for

subgroups of patients with HF, such as those defined by left ventricular ejection fraction⁷²; however, we were unable to perform a stratified analysis due to the limited phenotype data available at the time of HF diagnosis. To leverage the full potential of proteomics and genomics in understanding heart failure and identifying drug targets, there is a need to decompose heart failure into phenotypic components including those of cardiac dysfunction and fluid congestion which characterize this condition. ADM and CTSL1 are notable among our findings since their protective effect against the risk of heart failure was not explained by association with upstream risk factor traits. ADM is a circulating peptide hormone synthesized by endothelial and vascular smooth muscle cells, the biologically active form of which has been proposed as a marker and inhibitor of tissue fluid congestion, a hallmark feature of heart failure⁵⁵. Consistent with our results, it has been hypothesized that ADM may play a protective role in HF development and progression by maintaining vascular integrity, inducing vasodilatation, and inhibiting renin–angiotensin–aldosterone system⁵⁵.

Limitations

Whilst the clinical ascertainment of heart failure was consistent across the studies included in the observational analysis and in HF GWAS, the interpretation of our findings is limited by the lack of detailed phenotyping by etiology and phenotypes of cardiac structure and function. Our MR framework, including the prioritization of parameters for the multiverse analysis, was based upon prior studies of gene transcript exposure demonstrating robust and reproducible estimates⁷³; however, the scope of our multiverse analysis was limited by the high computational burden of the approach. There is a lack of consensus regarding the optimal approach to *cis*-MR and we were unable to empirically replicate our findings in an independent sample because none were available at the time of the study. It is possible for proteins with an important causal contribution to HF risk to have a null observational association in this study due to negative confounding or imprecision of the estimates. Given

that circulating protein concentrations are measured in a relative normalized protein expression unit²⁰, the derived effect estimates are rarely representative of the absolute magnitude of effect on HF and are not directly comparable across proteins. The expected causal direction of effects, however, can inform potential efficacy and on-target side effects, which can be formally investigated further in clinical trials. Further studies are needed to corroborate and extend our findings, to include a larger number of protein biomarkers and to explore the relationship of the identified proteins with disease subtypes. These studies will be enabled by the rapidly increasing availability of proteomic and genomic information at population scale from large healthcare-linked biobanks.

Conclusion

In conclusion, we evaluated 90 cardiovascular-related proteins through observational and Mendelian randomization analysis using population-based proteomic data and identified 7 candidate drug targets for heart failure. Of these, two proteins (ADM and Gal-3) are currently under evaluation in clinical trials for HF and five (CHI3L1, CSF-1, CTSL1, FGF-23 and MMP-12) represent novel putative therapeutic targets for HF. This study provides an example of the opportunities for human target prioritization that are enabled by emerging population-based genomic and proteomic data resources. Proteome-wide studies incorporating both direct association with target outcomes and genetic-based inference through Mendelian randomization are likely to provide important new tools for therapeutic target discovery and prioritization

Acknowledgements

We thank the participants of PIVUS, ULSAM, and studies included in HOMAGE, SCALLOP, and HERMES consortia. We thank Olink Proteomics for providing proteomics assays used in PIVUS, ULSAM, and studies in HOMAGE and SCALLOP consortia. We thank the investigators of consortia and research groups who performed GWAS analyses and made summary statistics data available to use in the present study. We acknowledge the use of the UCL Myriad High Performance Computing Facility (Myriad@UCL), and associated support services, in the completion of this work.

Author Contributions

A.H., A.M., R.T.L. and A.D.H. conceived and designed the study. J.S., L.L., J.Ä., and F.Z. provided data for observational meta-analysis. A.M. and R.T.L. provided data for Mendelian randomization analysis. A.H., M.G., and J.P.F. performed data analyses, with inputs from C.F., A.F.S., R.T.L., and A.D.H.. A.H. and R.T.L. wrote the initial draft, which was further reviewed and edited by M.G., C.F., A.F.S., R.K., and A.D.H.. A.M., A.D.H., and R.T.L. jointly supervised the work. All authors provided critical revisions in subsequent drafts and gave approval to the final version for submission. The corresponding author confirms that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Sources of Funding

This work is supported by the University College London (UCL) Hospitals National Institute for Health Research (NIHR) Biomedical Research Centre, the British Heart Foundation (BHF) Research Accelerator Award (AA/18/6/34223), and UK Research and Innovation / NIHR funded Multimorbidity Mechanism and Therapeutics Research Collaborative (MR/V033867/1). A. H. (FS/18/65/34186) and M.G. (FS/17/70/33482) acknowledge support by the BHF Cardiovascular Biomedicine PhD studentship. A.D.H. is an NIHR Senior

Investigator. A.F.S is supported by BHF grant PG/18/503383, and acknowledges support by grant R01 LM010098 from the National Institutes of Health (USA). R.K. acknowledges support by the Walker-Inman Endowment, the Mandel Foundation, and by grant R03 HL144812-01. L.L. is supported by a grant from the Swedish Heart-Lung Foundation. J.Ä. is supported by grants from Swedish Research Council (2019-01015 and 2020-00243), the Swedish Heart-Lung Foundation (20180343 and 20210357). R.T.L. is supported by a UK Research and Innovation Rutherford Fellowship hosted by Health Data Research UK (MR/S003754/1) and BigData@Heart Consortium funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074. C.F., A.F.S., and R.T.L. acknowledge additional support from UCL Hospitals NIHR Biomedical Research Centre.

Disclosures



A.F.S. has received Servier funding for an unrelated work. The views expressed in this article are the personal views of M.G.M and do not represent the views of her current employer, the European Medicines Agency. J.P.F. consults for Boehringer Ingelheim and has received research support from Boehringer Ingelheim, Novartis, AstraZeneca and Bayer through his institution. J.S. reports stock ownership in companies providing services to Amgen, AstraZeneca, Boehringer, Bayer, Eli Lilly, Itrim, Janssen, Novo Nordisk, Pfizer and Takeda, outside the submitted work. J.Ä. has served on advisory boards for AstraZeneca and Boehringer Ingelheim and received lecturing fees from AstraZeneca and Novartis, all unrelated to the present project. The remaining authors declare no competing interests.

Supplemental Materials

Supplemental Methods

Supplemental Figure 1

Supplemental Tables 1 - 8



Circulation

References

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola V-P, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37:2129–2200.
2. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. *JAMA*. 2004;292:344–350.
3. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. *N Engl J Med*. 2015;373:2314–2324.
4. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CSP, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA*. 2015;314:2251–2262.
5. Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, et al. Cardiovascular drug development: is it dead or just hibernating? *J Am Coll Cardiol*. 2015;65:1567–1582.
6. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R, Karlsson A, Santos R, et al. The druggable genome and support for target identification and validation in drug development. *Sci Transl Med* [Internet]. 2017;9:eaag1166. Available from: <http://dx.doi.org/10.1126/scitranslmed.aag1166>
7. Smith JG, Gerszten RE. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease. *Circulation*. 2017;135:1651–1664.
8. Stenemo M, Nowak C, Byberg L, Sundström J, Giedraitis V, Lind L, Ingelsson E, Fall T, Årnlöv J. Circulating proteins as predictors of incident heart failure in the elderly. *Eur J Heart Fail*. 2018;20:55–62.
9. Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bär C, Björkman J, Boccanelli A, Butler J, Clark A, et al. Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. *Circ Heart Fail*. 2019;12:e005897.
10. Egerstedt A, Berntsson J, Smith ML, Gidlöf O, Nilsson R, Benson M, Wells QS, Celik S, Lejonberg C, Farrell L, et al. Profiling of the plasma proteome across different stages of human heart failure. *Nat Commun*. 2019;10:5830.
11. Suhre K, McCarthy MI, Schwenk JM. Genetics meets proteomics: perspectives for large population-based studies. *Nat Rev Genet* [Internet]. 2021;22:19–37. Available from: <http://dx.doi.org/10.1038/s41576-020-0268-2>.
12. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44:512–525.
13. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ*. 2018;362:k601.
14. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyńska M, et al. Genetic drug target validation using Mendelian randomisation. *Nat Commun*. 2020;11:3255.
15. Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, Page K, Zhernakova DV, Wu Y, Peters J, et al. Genomic and drug target evaluation of 90

- cardiovascular proteins in 30,931 individuals. *Nat Metab.* 2020;2:1135–1148.
16. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P, et al. Genomic atlas of the human plasma proteome. *Nature.* 2018;558:73–79.
 17. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, Mindell JS, Kivimaki M, Brunner EJ, Whittaker JC, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. *Int J Epidemiol.* 2016;45:1600–1616.
 18. Assarsson E, Lundberg M, Holmquist G, Björkstén J, Thorsen SB, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. *PLoS One.* 2014;9:e95192.
 19. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman ÅK, Wilk JB, Morley MP, Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun.* 2020;11:163.
 20. What is NPX? - Olink [Internet]. [cited 2020 Nov 24];Available from: <https://www.olink.com/question/what-is-npx/>
 21. Jacobs L, Thijs L, Jin Y, Zannad F, Mebazaa A, Rouet P, Pinet F, Bauters C, Pieske B, Tomaschitz A, et al. Heart “omics” in AGEing (HOMAGE): design, research objectives and characteristics of the common database. *J Biomed Res.* 2014;28:349–359.
 22. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. *Arterioscler Thromb Vasc Biol.* 2005;25:2368–2375.
 23. Hedstrand H. A study of middle-aged men with particular reference to risk factors for cardiovascular disease. *Ups J Med Sci Suppl.* 1975;19:1–61.
 24. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, Rodondi N, Satterfield S, Bauer DC, Bibbins-Domingo K, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. *Arch Intern Med.* 2009;169:708–715.
 25. Mureddu GF, Agabiti N, Rizzello V, Forastiere F, Latini R, Cesaroni G, Masson S, Cacciatore G, Colivicchi F, Uguccioni M, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. *Eur J Heart Fail.* 2012;14:718–729.
 26. Mureddu GF, Tarantini L, Agabiti N, Faggiano P, Masson S, Latini R, Cesaroni G, Miceli M, Forastiere F, Scardovi AB, et al. Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from “PREDICTOR”, a population based-study in central Italy. *Eur J Heart Fail.* 2013;15:1102–1112.
 27. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. *Am J Cardiol.* 1999;84:1192–1197.
 28. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet.* 2002;360:1623–1630.
 29. Nanchen D, Stott DJ, Gussekloo J, Mooijaart SP, Westendorp RGJ, Jukema JW, Macfarlane PW, Cornuz J, Rodondi N, Buckley BM, et al. Resting heart rate and

- incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. *Eur J Heart Fail*. 2013;15:581–588.
30. VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to risk ratios. *Biometrics*. 2020;76:746–752.
 31. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med*. 2016;35:1880–1906.
 32. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization with fine-mapped genetic data: Choosing from large numbers of correlated instrumental variables. *Genet Epidemiol*. 2017;41:714–725.
 33. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7.
 34. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, Kang HM, Fuchsberger C, Danecek P, Sharp K, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48:1279–1283.
 35. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203–209.
 36. Steegen S, Tuerlinckx F, Gelman A, Vanpaemel W. Increasing Transparency Through a Multiverse Analysis. *Perspect Psychol Sci*. 2016;11:702–712.
 37. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Holmes MV, Minelli C, Relton CL, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res*. 2019;4:186.
 38. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol*. 2017;46:1734–1739.
 39. Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG, Bennett R, et al. Ensembl 2020. *Nucleic Acids Res*. 2020;48:D682–D688.
 40. Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*. 2015;47:1121–1130.
 41. Roselli C, Chaffin MD, Weng L-C, Aeschbacher S, Ahlberg G, Albert CM, Almgren P, Alonso A, Anderson CD, Aragam KG, et al. Multi-ethnic genome-wide association study for atrial fibrillation. *Nat Genet*. 2018;50:1225–1233.
 42. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, Tin A, Wang L, Chu AY, Hoppmann A, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nat Genet*. 2019;51:957–972.
 43. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G, Dimou N, Cabrera CP, Karaman I, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet*. 2018;50:1412–1425.
 44. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, Payne AJ, Steinthorsdottir V, Scott RA, Grarup N, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet*. 2018;50:1505–1513.
 45. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, Yengo L, Ferreira T, Marouli E, Ji Y, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet*. 2019;28:166–174.

46. Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, et al. ChEMBL: towards direct deposition of bioassay data. *Nucleic Acids Res.* 2019;47:D930–D940.
47. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. *Epidemiology.* 2017;28:30–42.
48. Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, Zdravkovic NS, Djukic AL, Arsenijevic NN, Lukic ML. Galectin-3 Deficiency Accelerates High-Fat Diet–Induced Obesity and Amplifies Inflammation in Adipose Tissue and Pancreatic Islets. *Diabetes.* 2013;62:1932–1944.
49. Levine JA, Jensen MD, Eberhardt NL, O’Brien T. Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth. *J Clin Invest.* 1998;101:1557–1564.
50. Lumbers T, Katsoulis M, Henry A, Mordi I, Lang C, Hemingway H, Langenberg C, Holmes M, Sattar N. Body mass index and heart failure risk: a cohort study in 1.5 million individuals and Mendelian randomisation analysis. *medRxiv.* Preprint posted online September 25, 2020. Available from: <https://doi.org/10.1101/2020.09.23.20200360>.
51. Harutyunyan M, Christiansen M, Johansen JS, Køber L, Torp-Petersen C, Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. *Immunobiology.* 2012;217:652–656.
52. Liu C-L, Guo J, Zhang X, Sukhova GK, Libby P, Shi G-P. Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials. *Nat Rev Cardiol.* 2018;15:351–370.
53. Sjaarda J, Gerstein H, Chong M, Yusuf S, Meyre D, Anand SS, Hess S, Paré G. Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. *J Am Coll Cardiol.* 2018;72:300–310.
54. Clinkenbeard EL, Noonan ML, Thomas JC, Ni P, Hum JM, Aref M, Swallow EA, Moe SM, Allen MR, White KE. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD. *JCI Insight* [Internet]. 2019;4:e123817. Available from: <http://dx.doi.org/10.1172/jci.insight.123817>.
55. Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Düngen H-D, et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application. *Eur J Heart Fail.* 2019;21:163–171.
56. Lau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, López B, Díez J, Wang TJ, Ho JE. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. *JACC Basic Transl Sci.* 2021;6:12–21.
57. Liu T, Luo S, Libby P, Shi G-P. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. *Pharmacol Ther.* 2020;213:107587.
58. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al. Proteomics. Tissue-based map of the human proteome. *Science.* 2015;347:1260419.
59. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. *J Am Coll Cardiol.* 2012;60:1249–1256.
60. Ferraro RA, Ogunmoroti O, Zhao D, Ndumele CE, Rao V, Pandey A, Larson NB, Bielinski SJ, Michos ED. Hepatocyte Growth Factor and Incident Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA). *J Card Fail.* 2021;27:981–990.
61. Frankel DS, Vasan RS, D’Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ, Meigs JB.

- Resistin, adiponectin, and risk of heart failure the Framingham offspring study. *J Am Coll Cardiol*. 2009;53:754–762.
62. Borst O, Schaub M, Walker B, Sauter M, Muenzer P, Gramlich M, Mueller K, Geisler T, Lang F, Klingel K, et al. CXCL16 is a novel diagnostic marker and predictor of mortality in inflammatory cardiomyopathy and heart failure. *Int J Cardiol*. 2014;176:896–903.
 63. Kanagala P, Arnold JR, Singh A, Chan DCS, Cheng ASH, Khan JN, Gulsin GS, Yang J, Zhao L, Gupta P, et al. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach. *PLoS One*. 2020;15:e0232280.
 64. Petermann I, Mayer C, Stypmann J, Biniossek ML, Tobin DJ, Engelen MA, Dandekar T, Grune T, Schild L, Peters C, et al. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. *FASEB J*. 2006;20:1266–1268.
 65. Sun M, Chen M, Liu Y, Fukuoka M, Zhou K, Li G, Dawood F, Gramolini A, Liu PP. Cathepsin-L contributes to cardiac repair and remodelling post-infarction. *Cardiovasc Res*. 2011;89:374–383.
 66. Zhao M-M, Yang W-L, Yang F-Y, Zhang L, Huang W-J, Hou W, Fan C-F, Jin R-H, Feng Y-M, Wang Y-C, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. *Signal Transduct Target Ther*. 2021;6:134.
 67. Ho JE, Lyass A, Courchesne P, Chen G, Liu C, Yin X, Hwang S-J, Massaro JM, Larson MG, Levy D. Protein Biomarkers of Cardiovascular Disease and Mortality in the Community. *J Am Heart Assoc* [Internet]. 2018;7: e008108. Available from: <http://dx.doi.org/10.1161/JAHA.117.008108>
 68. Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, Sterling DG, Williams SA. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. *JAMA*. 2016;315:2532–2541.
 69. Geelhoed B, Börschel CS, Niiranen T, Palosaari T, Havulinna AS, Fouodo CJK, Scheinhardt MO, Blankenberg S, Jousilahti P, Kuulasmaa K, et al. Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort. *Europace*. 2020;22:1463–1469.
 70. Wang Z, Yang F, Ma M, Bao Q, Shen J, Ye F, Xie X. The impact of growth differentiation factor 15 on the risk of cardiovascular diseases: two-sample Mendelian randomization study. *BMC Cardiovasc Disord*. 2020;20:462.
 71. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. *Int J Epidemiol*. 2016;45:1866–1886.
 72. Adamo L, Yu J, Rocha-Resende C, Javaheri A, Head RD, Mann DL. Proteomic Signatures of Heart Failure in Relation to Left Ventricular Ejection Fraction. *J Am Coll Cardiol*. 2020;76:1982–1994.
 73. Ndungu A, Payne A, Torres JM, van de Bunt M, McCarthy MI. A Multi-tissue Transcriptome Analysis of Human Metabolites Guides Interpretability of Associations Based on Multi-SNP Models for Gene Expression. *Am J Hum Genet*. 2020;106:188–201.

Table 1. Summary of Study Characteristics Included in the Observational Meta-Analysis

Reporting Study	Study design	Cohort	Median age at baseline (years)	Median Follow-Up (years) [range]	HF events / N total sample
Ferreira <i>et al.</i> (2019)	Nested-matched case-control (logistic regression)	HOMAGE ²¹ discovery			
		Health ABC ²⁴	74	8.3 [0.0–14.4]	215 / 648
		PREDICTOR ^{25,26}	77	2.5 [0.2–3.8]	15 / 44
		PROSPER ^{27–29}	77	2.0 [0.2–3.9]	56 / 185
		HOMAGE ²¹ validation			
		Health ABC ²⁴	73	9.0 [0.1–14.4]	109 / 208
		PREDICTOR ^{25,26}	76	2.2 [0.1–4.5]	29 / 58
		PROSPER ^{27–29}	76	1.8 [0.1–3.8]	138 / 290
Stenemo <i>et al.</i> (2018)	Time-to-event analysis (Cox proportional hazards regression)	PIVUS ²²	70.2	10.0 [0.1–10.9]	80 / 901
		ULSAM ²³	77.8	8.0 [0.2–10.9]	90 / 685

Table 2. Summary of Druggability and Clinical Development Activity for HF-Associated with Causal Associations on Mendelian Randomisation Analysis

Target	Status	Compound name	Molecule type	Action type	Clinical development activities
ADM (adrenomedullin)	in development	adrecizumab [†]	antibody	redistributing interstitial to plasma ADM	Phase I/II trials: Septic shock (NCT03085758) [†] , Cardiogenic shock (NCT03989531) [†] , Acute heart failure (NCT04252937) [†]
CHI3L1 (chitinase 3-like 1)	druggable*	—	antibody*	—	—
CSF-1 (colony stimulating factor 1)	in development	MCS-110 [‡] (CHEMBL2109512)	antibody	antagonist	Phase I/II trials: Melanoma, Stomach Neoplasms, Breast Neoplasms
		PD-360324 [‡] (CHEMBL2109513)	antibody	antagonist	Phase I/II trials: Arthritis, Rheumatoid, Lupus Erythematosus, Cutaneous Sarcoidosis
CTSL1 (cathepsin L)	druggable*	—	small molecule*	—	—
FGF-23 (fibroblast growth factor 23)	approved	burosumab [‡] (CHEMBL3707326)	antibody	antagonist	Approved for: X-linked Hypophosphatemia, Hypophosphatemic Rickets
Gal-3 (galectin-3)	in development	GB1211 [†]	small molecule*	antagonist	Phase I/II trials: Non-alcoholic steatohepatitis (NCT04607655) [†]
	in development	Modified Citrus Pectin (MCP)	carbohydrate oral supplement	antagonist	Phase I/II trials: Hypertension (NCT01960946) [†]
MMP-12 (matrix metalloproteinase 12)	in development	FP-025 [†]	small molecule	antagonist	Phase I/II trials: Asthma (NCT03858686) [†]
		MARIMASTAT [‡] (CHEMBL279785)	small molecule	antagonist	Phase III trials [‡] : Lung Neoplasms, Breast Neoplasms
KIM-1 (kidney injury molecule 1)	Not currently listed as druggable	—	—	—	—

*data from druggable gene list⁶[†]data from [ClinicalTrials.gov](https://clinicaltrials.gov) (clinical trial ID in brackets)[‡]data from ChEMBL release 27⁴⁶ (compound ID in brackets)

Figure Legends

Figure 1. A Flowchart of the Study Design and a Schematic Illustration of *cis*-Mendelian Randomization. MR, Mendelian randomization; LD, linkage disequilibrium; GWAS, genome-wide association study; pQTL, protein quantitative trait loci

Figure 2. Observational and Mendelian Randomization Estimates of Protein - Heart Failure Association. **a.** Circular heatmap of association from 40 proteins associated with incident heart failure in observational studies ($P < 0.05/83 = 0.0006$). The two circular lanes refer to results from two analyses: 1) observational analysis; and 2) *cis*-Mendelian randomization with partially correlated instruments. Color represents direction of effect and strength of association with heart failure measured by P-value. **b.** Forest plot of risk ratio (hazard ratio from observational analysis and odds ratio from MR analysis) from 17 proteins associated with heart failure in MR analysis ($P < 0.05/40 = 0.001$). Colored dots and error bars indicate the point estimate and 95% confidence intervals. The grey violin plots around the MR estimates illustrate the distributions of odds ratio point estimates estimated from combinations of up to 30 instrument selection parameters and 4 MR models in multiverse sensitivity analysis, with medians of distribution shown as vertical lines within the violin plot. Proteins with consistent direction of effect as indicated by multiverse sensitivity analysis are highlighted in ***bold and italic font***.

Figure 3. Estimated Effect of Prioritized Circulating Protein Levels with Heart Failure and Related Traits. Left panel shows approximate relative risks of heart failure per doubling circulating protein levels as estimated with meta-analysis of observational data and *cis*-MR. Right panel shows a matrix of estimated causal effect size of prioritized circulating protein levels (rows) on HF and related traits (columns) from *cis*-MR analysis as represented by

bullet points. The size of the bullet represents the magnitude of estimated causal effect measured in absolute Z-score. Bullet points with a darker shade indicate associations that survived multiple testing at $P\text{-value} < 0.0009$ ($\alpha = 0.05 / (8 \text{ proteins} * 7 \text{ traits, excluding HF})$). Red color indicates a risk / trait -increasing effect and blue color indicates a risk / trait -decreasing effect. Abbreviations: MR, Mendelian randomization; CI, confidence interval; CAD, coronary artery disease; AF, atrial fibrillation; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2D, type 2 diabetes; BMI, body mass index.



Circulation

STAGE 1: Observational analysis

Association of circulating protein levels with incident heart failure

Ferreira et al. (2019)
(Olink® CVD-II, CVD-III, INF)

Stenemo et al. (2018)
(Olink® CVD-I)

90 CVD-associated circulating proteins

Meta-analysis of observational association with incident HF

46 proteins with $P \geq 0.05/90$

44 HF-associated proteins
($P < 0.05 / 90$)

Genetic association with circulating protein levels

Folkersen et al. (2020)
(Olink® CVD-I)

88 proteins with autosome-wide genetic association summary statistics

cis- instrument selection

5 X-chromosome proteins
8 autosomal proteins with no suitable *cis*-genetic instrument

75 proteins with ≥ 1 cis-genetic instruments

40 HF-associated proteins evaluable by cis-MR

STAGE 2: Causal appraisal and drug target profiling

Are observationally-associated circulating proteins causally related to HF?

Two-sample cis MR

17 proteins with evidence of causal effect on HF
($P < 0.05 / 40$)

Are causal estimates from MR robust?

Multiverse sensitivity analysis
Combinations of 30 instrument selection and up to 4 MR models per protein


8 proteins with robust causal effect estimates on HF

What are the effects on related traits?



Are these proteins druggable?

Cross-trait two-sample cis MR
Estimate causal effects on AF, BMI, T2DM, CAD, eGFR, SBP, DBP

Drug target profiling
Cross-reference with ChEMBL, druggable genome, and ClinicalTrials.gov databases




Downloaded from <http://ahajournals.org> by on March 18, 2022



Association with Heart failure Relative risk (95% CI)

cis-MR estimate on HF-related traits



Absolute Z-score ● 5 ● 10 ● 15 Direction ● Positive ● Negative